News of Note—Kite IND, RXi I-O targets and Mitobridge DMD test

Kite's IND, RXi's I-O picks and Mitobridge phase 1.

Kite Pharma, which in a tight race with Novartis to gain U.S. approval for the first-ever CAR-T med later this year, said it has submitted an IND app with the FDA for a Phase 1, first-in-human trial of KITE-585, another of its CAR-T therapies, to target B-cell maturation antigen (BCMA) in patients with relapsed/refractory multiple myeloma. Release

> RNAi company RXi Pharmaceuticals said it has picked two self-delivering RNAi (sd-rxRNA) compounds from its immuno-oncology pipeline for preclinical development. The compounds, RXI-762 and RXI-804, suppress the expression of immune checkpoint proteins PD-1 and TIGIT. Statement

Mitobridge says it has hit a “key milestone” with the start of the first-in-human Phase 1 test of its PPAR-delta modulator, MA-0211 in healthy volunteers, which will provide the basis for future studies in Duchenne Muscular Dystrophy patients. Release

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.